Overview

Comparison of Efficacy of Cefotaxime, Ceftriaxone, and Ciprofloxacin for the Treatment of SBP in Patients With LC

Status:
Completed

Trial end date:
2018-06-01

Target enrollment:
0

Participant gender:
All

Summary

Spontaneous bacterial peritonitis (SBP) is one of the most serious complications of liver cirrhosis. Mainstay of treatment for SBP is use of proper antibiotics. Although, several antibiotics including cefotaxime, ceftriaxone, or ciprofloxacin are being used, it is unclear which drug is most effective. Our aim of study is to compare the efficacy of the three current antibiotics for the treatment of SBP in patients with liver cirrhosis. The primary hypothesis is that the efficacy of all the antibiotics will not significantly different. This is non-inferiority trial.

Phase:

Phase 4

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Korea University

Treatments:

Cefotaxime
Cefoxitin
Ceftriaxone
Ciprofloxacin

Criteria

Inclusion Criteria:

1. Liver cirrhosis patients with ascites

2. Ascitic fluid PMN cell count >250/mm3

3. Age: 16~70 years old

Exclusion Criteria:

1. Allergic to 3rd generation cephalosporin or quinolone

2. Antibiotics within 2 weeks

3. Open abdominal surgery within 4 weeks

4. Evidence of 2ndary peritonitis, intrabdominal hemorrhage, pancreatitis, Tb
peritonitis, or peritoneal carcinomatosis

5. HCC with portal vein thrombosis

6. Pregnant woman

7. HIV positive